|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A tandomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose lowering drugs in insulin-naive people with type 2 diabetes显示文摘 | Rosenstock J Davies M Home PD | 2008 | Diabetologia2008，51，： | 1 |
| 2 | A randomised,52week,treat-to-target trial comparing insulin detemir with insulin glargine when administered as add on to glucose-lowering drugs in insulin-naive people with type 2 diabetes显示文摘 | Rosenstock J Davies M Home PD | | 0，，： | 1 |
| 3 | Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue , insulin aspart, in healthy volunteer 显示文摘 | Home PD Barriocanal A Lindholm A | 1999 | Eur J Clin Pharmacol1999，55，3： | 1 |
| 4 | Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes ( RECORD ): study design and protocol 显示文摘 | Home PD Pocock SJ Beck-Nielsen H | 2005 | Diabetologia2005，48，9： | 1 |
| 5 | premixed human insulin 30/70 twice daily:a randomized trail in type 1 and type 2 diabetic patients 显示文摘 | BOEHM BO HOME PD BEHREND C Premixed insulin aspart 30 vs | 2002 | Diabet Med2002，19，5： | 1 |
| 6 | Combined randomised controlled trial experience of malignancies in studies using insulin glargine 显示文摘 | Home PD Lagarenne P | 2009 | Diabetologia2009，52，24： | 1 |
| 7 | A randomised, 52-week, treat- to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes显示文摘 | Rosenstock J Davies M Home PD | 2008 | Diabetologia2008，51，3： | 1 |
| 8 | Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes 显示文摘 | Lindholm A Jensen L B Home PD | 2002 | Diabetes Care2002，25，5： | 1 |
| 9 | Safety and eff/cacy of long term exposure to biphasic insulin aspart compared with biphasic human insulin in people with type 2 diabetes 显示文摘 | BOEHM BO HOME PD RASTAM J | 2003 | Diabetologia2003，46，2： | 1 |
| 10 | Rosiglita- zone evaluated for cardiovascular outcomes in oral agent combina- tion therapy for type 2 diabetes (RECORD) : a multicentre, ran- domized, open-label trial 显示文摘 | HOME PD POCOCK SJ BECK-NIELSEN H | 2009 | Lancet2009，373，9681： | 1 |
| 11 | Rosiglita- zone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol 显示文摘 | Home PD Pocock SJ Beck-Nielsen H | 2005 | Diabetologia2005，48，9： | 1 |
| 12 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a muhicentre, randomised,open-label trial显示文摘 | Home PD Pocock SJ Beck-Nielsen H | 2009 | Lancet2009，373，9681： | 1 |
| 13 | A crossver comparison of continnuous subcutaneous insulin infusion (CSⅡ)against multiple insulin injections in insulin - dependent diabetic subject improved control with CSⅡ 显示文摘 | Home PD Capaldo B Burrin TM | 1982 | Diabetes Care1982，5，： | 1 |
| 14 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes(RECORD) : a muhicentre, randomised, open-label trial 显示文摘 | Home PD Pocock SJ Nielsen HB | 2009 | Lancet2009，373，9681： | 1 |
| 15 | The role of asymmetric dimethylarginine(ADMA)in endothelial dysfunction and cardiovascular disease显示文摘 | Sibal L Agarwal SC Home PD | 2010 | Curr Cardiol Rev2010，6，2： | 1 |
| 16 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes(RECORD):a multicentre,randomised,open-label trial显示文摘 | Home PD Pocock SJ Beck-Nielsen H | 2009 | Lancet2009，373，9681： | 1 |
| 17 | Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD) : study design and protocol显示文摘 | Home PD pocock SJ Beck-nielsen H | 2005 | Diabetologia2005，48，9： | 1 |
| 18 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD):a multicentre,randomised,open-label trial显示文摘 | Home PD Pocock SJ Beck-Nielsen H | 2009 | Lancet2009，373，： | 1 |
| 19 | Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glarglne with less weight gain 显示文摘 | Rosenstock J Davies M Home PD | 2006 | Diabetes2006，55，1： | 1 |
| 20 | Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: a randomized trail in type 1 and type 2 diabetic patients显示文摘 | Boehm BO Home PD Behrend C | 2002 | Diabet Med2002，19，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员